UBS keeps USD 15.00 target for Kura Oncology stock
Published on 10/15/2026 at 22:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst outlook and scheduled date
- UBS reiterated a USD 15.00 target for Kura Oncology on October 5, 2026.
- Second-quarter revenue reached USD 20.87 million against USD 20.16 million expected.
- Kura Oncology stock costs EUR 8.67 at Lang & Schwarz on October 15, 2026 at 10:09 p.m. CEST.
- Kura Oncology is scheduled to report earnings on November 3, 2026.
UBS reiterated a Buy rating and a USD 15.00 price target for Kura Oncology on October 5, 2026, according to Investing.com. Against a USD 9.70 Nasdaq price on October 15, 2026, that target stands 54.64 percent above the price. At Lang & Schwarz, Kura Oncology stock was trading at EUR 8.67 on October 15, 2026 at 10:09 p.m. CEST.
Second-quarter revenue reached USD 20.87 million
Kura Oncology reported second-quarter 2026 revenue of USD 20.87 million against USD 20.16 million expected. Its adjusted loss was USD 0.77 per share, compared with an expected USD 0.88 loss, according to Investing.com. The figures cover the quarter reported on August 12, 2026, and give the commercial launch of KOMZIFTI a measurable revenue base.
Stock sits within a USD 7.36 to USD 13.90 range
The Nasdaq price of USD 9.70 on October 15, 2026 stood 30.22 percent below the 52-week high of USD 13.90 and 31.79 percent above the low of USD 7.36. Trading volume was 1,643,389 shares against an average of 1,796,040 shares for the same market-data timestamp.
Valuation and November reporting date
Kura Oncology had a market capitalization of USD 862.9 million and a trailing P/E ratio of minus 2.88 on October 15, 2026. Yahoo Finance lists Nasdaq as the primary exchange and November 3, 2026 as the next earnings date.
Comparison with peers
Kura Oncology (Nasdaq, USD): P/E minus 2.88, market capitalization USD 862.9 million
Syndax Pharmaceuticals (Nasdaq, USD): daily change 0.89 percent, P/E minus 5.42, market capitalization USD 1.2 billion
Rigel Pharmaceuticals (Nasdaq, USD): daily change 0.92 percent, P/E 2.90, market capitalization USD 882.6 million
Price remains the daily frame
The analyst target gives Kura Oncology a dated valuation reference, while the latest reported quarter provides an operating comparison against expectations. The next scheduled earnings date is November 3, 2026.
The further course of trading is shown by the continuously updated real-time quote of Kura Oncology stock.
Kura Oncology market data
- Company: Kura Oncology, Inc.
- ISIN: US50127T1097
- Ticker: KURA
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 15, 2026 at 10:09 p.m. CEST: EUR 8.67
- Market capitalization: USD 862.9 million (as of October 15, 2026)
- 52-week range: USD 7.36-13.90 (as of October 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 3, 2026
Market context: Market report Nasdaq Composite.
